E3 ubiquitin ligases as cancer targets and biomarkers

Neoplasia

Volumn 8, Issue 8, 2006, Pages 645-654

  Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Apoptosis; Biomarkers; Cancer targets; E3 ubiquitin ligases; Protein degradation

Indexed keywords

ARYL SULFONAMIDE; CASPASE; CULLIN; F BOX PROTEIN; HLI 98; INHIBITOR OF APOPTOSIS PROTEIN; LIGASE INHIBITOR; MI 17; NUTLIN; PROTEIN MDM2; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; S PHASE KINASE ASSOCIATED PROTEIN; SULFONAMIDE; TRIPEPTIDE; TUMOR MARKER; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; PROTEIN;

CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; CELLULAR DISTRIBUTION; DISEASE MARKER; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; UBIQUITINATION; ANIMAL; APOPTOSIS; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; PROTEINS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 33748521536     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06376     Document Type: Review

References (150)

1. Ciechanover A (1998). The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17 (24), 7151-7160.
2. Hicke L, Schubert HL, and Hill CP (2005). Ubiquitin-binding domains. Nat Rev Mol Cell Biol 6 (8), 610-621.
3. Pickart CM (2001). Ubiquitin enters the new millennium. Mol Cell 8 (3), 499-504.
4. Hershko A and Ciechanover A (1998). The ubiquitin system. Annu Rev Biochem 67, 425-479.
5. Varshavsky A (2003). The N-end rule and regulation of apoptosis. Nat Cell Biol 5 (5), 373-376.
6. Ditzel M, Wilson R, Tenev T, Zacharious A, Paul A, Deas E, and Meier P (2003). Degradation of DIAP1 by the N-end rule pathway is essential for regulating apoptosis. Nat Cell Biol 5 (5), 467-473.
7. Scheffner M, Huibregtse JM, Vierstra RD, and Howley PM (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (3), 495-505.
8. Scheffner M, Nuber U, and Huibregtse JM (1995). Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373 (6509), 81-83.
9. Schwarz SE, Rosa JL, and Scheffner M (1998). Characterization of human HECT domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem 273 (20), 12148-12154.
10. Freemont PS (2000). RING for destruction? Curr Biol 10 (2), R84- R87.
11. Saurin AJ, Borden KL, Boddy MN, and Freemont PS (1996). Does this have a familiar RING? Trends Biochem Sci 21 (6), 208-214.
12. Mani A and Gelmann EP (2005). The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23 (21), 4776-4789.
13. Nakayama KI and Nakayama K (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6 (5), 369-381.
14. Cahilly-Snyder L, Yang-Feng T, Francke U, and George DL (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 13 (3), 235-244.
15. Haupt Y, Maya R, Kazaz A, and Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature 387 (6630), 296-299.
16. Kubbutat MH, Jones SN, and Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature 387 (6630), 299-303.
17. Honda R, Tanaka H, and Yasuda H (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420 (1), 25-27.
18. Honda R and Yasuda H (2000). Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19 (11), 1473-1476.
19. Fang S, Jensen JP, Ludwig RL, Vousden KH, and Weissman AM (2000). Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275 (12), 8945-8951.
20. Montes de Oca Luna R, Wagner DS, and Lozano G (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (6553), 203-206.
21. de Rozieres S, Maya R, Oren M, and Lozano G (2000). The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19 (13), 1691-1697.
22. Sun Y (2006). p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 45 (6), 409-415.
23. Wasylyk C, Salvi R, Argentini M, et al. (1999). p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18 (11), 1921-1934.
24. Duncan SJ, Cooper MA, and Williams DH (2003). Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem Commun (Camb) (3), 316-317.
25. Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, and Zhang R (2002). Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med 8 (4), 185-199.
26. Wang H, Yu D, Agrawal S, and Zhang R (2003). Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54 (3), 194-205.
27. Liu TG, Yin JQ, Shang BY, et al. (2004). Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther 11 (11), 748-756.
28. Yang Y, Ludwig RL, Jensen JP, et al. (2005). Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (6), 547-559.
29. Ding K, Lu Y, Nikolovska-Coleska Z, et al. (2005). Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 127 (29), 10130-10131.
30. Issaeva N, Bozko P, Enge M, et al. (2004). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10 (12), 1321-1328.
31. Vassilev LT, Vu BT, Graves B, et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (5659), 844-848.
32. Kussie PH, Gorina S, Marechal V, et al. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 (5289), 948-953.
33. Zhang Z and Zhang R (2005). p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5 (1), 9-20.
34. Dornan D, Wertz I, Shimizu H, et al. (2004). The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (6987), 86-92.
35. Leng RP, Lin Y, Ma W, et al. (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112 (6), 779-791.
36. Dornan D, Bheddah S, Newton K, et al. (2004). COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 64 (20), 7226-7230.
37. Duan W, Gao L, Druhan LJ, et al. (2004). Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst 96 (22), 1718-1721.
38. Salvesen GS and Duckett CS (2002). IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3 (6), 401-410.
39. Deveraux QL and Reed JC (1999). IAP family proteins-suppressors of apoptosis. Genes Dev 13 (3), 239-252.
40. Ashhab Y, Alian A, Polliack A, Panet A, and Yehuda DB (2001). Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 495 (1-2), 56-60.
41. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, and Dixit VM (2000). ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10 (21), 1359-1366.
42. Yang YL and Li XM (2000). The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10 (3), 169-177.
43. Vaux DL and Silke J (2005). IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6 (4), 287-297.
44. Shi Y (2002). Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9 (3), 459-470.
45. Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M, and Salvesen GS (2005). XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 24 (3), 645-655.
46. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, and Takahashi R (2001). X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J Biol Chem 276 (29), 27058-27063.
47. Wu G, Chai J, Suber TL, et al. (2000). Structural basis of IAP recognition by Smac/DIABLO. Nature 408 (6815), 1008-1012.
48. Chai J, Du C, Wu JW, Kyin S, Wang X, and Shi Y (2000). Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406 (6798), 855-862.
49. Holcik M, Gibson H, and Korneluk RG (2001). XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6 (4), 253-261.
50. Li J, Feng Q, Kim JM, et al. (2001). Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142 (1), 370-380.
51. Sasaki H, Sheng Y, Kotsuji F, and Tsang BK (2000). Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60 (20), 5659-5666.
52. Chen J, Wu W, Tahir SK, et al. (2000). Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2 (3), 235-241.
53. Olie RA, Simoes-Wust AP, Baumann B, et al. (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 (11), 2805-2809.
54. Hu Y, Cherton-Horvat G, Dragowska V, et al. (2003). Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo vivo. Clin Cancer Res 9 (7), 2826-2836.
55. Yonesaka K, Tamura K, Kurata T, et al. (2006). Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 118 (4), 812-820.
56. Yamaguchi Y, Shiraki K, Fuke H, et al. (2005). Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand-and chemotherapeutic agent-induced cell death. Oncol Rep 14 (5), 1311-1316.
57. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, and Borden EC (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11 (8), 915-923.
58. Fulda S, Wick W, Weller M, and Debatin KM (2002). Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo vivo. Nat Med 8 (8), 808-815.
59. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, and Kaufmann SH (2002). Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ situ. J Biol Chem 277 (46), 44236-44243.
60. Guo F, Nimmanapalli R, Paranawithana S, et al. (2002). Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative (BMS 247550)- and Apo-2L/TRAIL-induced apoptosis. Blood 99 (9), 3419-3426.
61. Mizukawa K, Kawamura A, Sasayama T, Tanaka K, Kamei M, Sasaki M, and Kohmura E (2006). Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines. J Neuro-Oncol 77 (3), 247-255.
62. Schimmer AD, Dalili S, Batey RA, and Riedl SJ (2006). Targeting XIAP for the treatment of malignancy. Cell Death Differ 13 (2), 179-188.
63. Oost TK, Sun C, Armstrong RC, et al. (2004). Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47 (18), 4417-4426.
64. Sun H, Nikolovska-Coleska Z, Yang CY, et al. (2004). Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem 47 (17), 4147-4150.
65. Nikolovska-Coleska Z, Xu L, Hu Z, et al. (2004). Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47 (10), 2430-2440.
66. Wu TY, Wagner KW, Bursulaya B, Schultz PG, and Deveraux QL (2003). Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol 10 (8), 759-767.
67. Schimmer AD, Welsh K, Pinilla C, et al. (2004). Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (1), 25-35.
68. Carter BZ, Gronda M, Wang Z, et al. (2005). Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105 (10), 4043-4050.
69. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, and Harran PG (2004). A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305 (5689), 1471-1474.
70. Bockbrader KM, Tan M, and Sun Y (2005). A small molecule Smacmimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24 (49), 7381-7388.
71. Hu S and Yang X (2003). Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem 278 (12), 10055-10060.
72. MacFarlane M, Merrison W, Bratton SB, and Cohen GM (2002). Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277 (39), 36611-36616.
73. Suzuki Y, Nakabayashi Y, and Takahashi R (2001). Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 98 (15), 8662-8667.
74. Morizane Y, Honda R, Fukami K, and Yasuda H (2005). X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO. J Biochem (Tokyo) 137 (2), 125-132.
75. Deshaies RJ (1999). SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15, 435-467.
76. Sun Y, Tan M, Duan H, and Swaroop M (2001). SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid Redox Signal 3 (4), 635-650.
77. Zheng N, Schulman BA, Song L, et al. (2002). Structure of the Cul1-Rbx1-Skp1-F box Skp2 SCF ubiquitin ligase complex. Nature 416 (6882), 703-709.
78. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, and Harper JW (2004). Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18 (21), 2573-2580.
79. skp2 complex through phosphorylated Thr187 in p27. Cur Biol 9, 661-664.
80. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, and Hershko A (2003). Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 278 (28), 25752-25757.
81. Kamura T, Hara T, Kotoshiba S, et al. (2003). Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci USA 100 (18), 10231-10236.
82. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, and Tansey WP (2003). Skp2 regulates Myc protein stability and activity. Mol Cell 11 (5), 1177-1188.
83. von der Lehr N, Johansson S, Wu S, et al. (2003). The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 11 (5), 1189-1200.
84. Guardavaccaro D, Kudo Y, Boulaire J, et al. (2003). Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4 (6), 799-812.
85. Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann JD, and Jackson PK (2003). Prophase destruction of Emi1 by the SCF(beta-TrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell 4 (6), 813-826.
86. Yaron A, Hatzubai A, Davis M, et al. (1998). Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 396 (6711), 590-594.
87. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, and Harper JW (1999). The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 13 (3), 270-283.
88. Spencer E, Jiang J, and Chen ZJ (1999). Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev 13 (3), 284-294.
89. Suzuki H, Chiba T, Kobayashi M, et al. (1999). IkappaBalpha ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, betaTrCP1 and betaTrCP2. Biochem Biophys Res Commun 256 (1), 127-132.
90. Fuchs SY, Chen A, Xiong Y, Pan ZQ, and Ronai Z (1999). HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene 18 (12), 2039-2046.
91. Hatakeyama S, Kitagawa M, Nakayama K, et al. (1999). Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci USA 96 (7), 3859-3863.
92. Latres E, Chiaur DS, and Pagano M (1999). The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18 (4), 849-854.
93. Hart M, Concordet JP, Lassot I, et al. (1999). The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9 (4), 207-210.
94. Kitagawa M, Hatakeyama S, Shirane M, et al. (1999). An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 18 (9), 2401-2410.
95. Masuda TA, Inoue H, Sonoda H, et al. (2002). Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62 (13), 3819-3825.
96. Shim EH, Johnson L, Noh HL, et al. (2003). Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 63 (7), 1583-1588.
97. Latres E, Chiarle R, Schulman BA, et al. (2001). Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 98 (5), 2515-2520.
98. Yokoi S, Yasui K, Saito-Ohara F, et al. (2002). A novel target gene, SKP2 SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 161 (1), 207-216.
99. Katagiri Y, Hozumi Y, and Kondo S (2006). Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo vivo. J Dermatol Sci.
100. Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, and Takata T (2005). Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 4 (3), 471-476.
101. Lee SH and McCormick F (2005). Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med 83 (4), 296-307.
102. Sumimoto H, Yamagata S, Shimizu A, et al. (2005). Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 12 (1), 95-100.
103. Jiang F, Caraway NP, Li R, and Katz RL (2005). RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 24 (21), 3409-3418.
104. Muerkoster S, Arlt A, Sipos B, et al. (2005). Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 65 (4), 1316-1324.
105. Belaidouni N, Peuchmaur M, Perret C, Florentin A, Benarous R, and Besnard-Guerin C (2005). Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice. Oncogene 24 (13), 2271-2276.
106. Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, and Fuchs SY (2005). Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res 65 (5), 1904-1908.
107. Duan H, Wang Y, Aviram M, et al. (1999). SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol Cell Biol 19, 3145-3155.
108. Sun Y (1999). Alteration of SAG mRNA in human cancer cell lines: requirement for the RING finger domain for apoptosis protection. Carcinogenesis 20, 1899-1903.
109. Yang GY, Pang L, Ge HL, et al. (2001). Attenuation of ischemia-induced mouse brain injury by SAG, a redox- inducible antioxidant protein. J Cereb Blood Flow Metab 21 (6), 722-733.
110. Chanalaris A, Sun Y, Latchman DS, and Stephanou A (2003). SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol 35 (3), 257-264.
111. Duan H, Tsvetkov LM, Liu Y, et al. (2001). Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: association with inhibition of p27 accumulation. Mol Carcinog 30 (1), 37-46.
112. Huang Y, Duan H, and Sun Y (2001). Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but its antisense transfection inhibits tumor cell growth. Mol Carcinog 30, 62-70.
113. Sun Y (2005). Overview of approaches for screening for ubiquitin ligase inhibitors. Methods Enzymol 399, 654-663.
114. Wu K, Fuchs SY, Chen A, et al. (2000). The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 20 (4), 1382-1393.
115. Furukawa M, Ohta T, and Xiong Y (2002). Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins. J Biol Chem 277 (18), 15758-15765.
116. Swaroop M, Wang Y, Miller P, et al. (2000). Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: chip profiling implicates its role in cell cycle regulation. Oncogene 19, 2855-2866.
117. Huang J, Sheung J, Dong G, Coquilla C, Daniel-Issakani S, and Payan DG (2005). High-throughput screening for inhibitors of the E3 ubiquitin ligase APC. Methods Enzymol 399, 740-754.
118. Cardozo T and Abagyan R (2005). Druggability of SCF ubiquitin ligase-protein interfaces. Methods Enzymol 399, 634-653.
119. Huang KS and Vassilev LT (2005). High-throughput screening for inhibitors of the cks1-skp2 interaction. Methods Enzymol 399, 717-728.
120. Hao B, Zheng N, Schulman BA, et al. (2005). Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell 20 (1), 9-19.
121. Semple JW and Duncker BP (2004). ORC-associated replication factors as biomarkers for cancer. Biotechnol Adv 22 (8), 621-631.
122. Rhodes DR and Chinnaiyan AM (2004). Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann N Y Acad Sci 1020, 32-40.
123. Freedman DA, Wu L, and Levine AJ (1999). Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55 (1), 96-107.
124. Zhang, Wang H (2000). MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 6 (4), 393-416.
125. Momand J, Jung D, Wilczynski S, and Niland J (1998). The MDM2 gene amplification database. Nucleic Acids Res 26 (15), 3453-3459.
126. Rayburn E, Zhang R, He J, and Wang H (2005). MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5 (1), 27-41.
127. Tamm I, Kornblau SM, Segall H, et al. (2000). Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6 (5), 1796-1803.
128. Tamm I, Richter S, Oltersdorf D, et al. (2004). High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 10 (11), 3737-3744.
129. Carter BZ, Kornblau SM, Tsao T, et al. (2003). Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 102 (12), 4179-4186.
130. Ferreira CG, van der Valk P, Span SW, et al. (2001). Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically linked resected non-small cell lung cancer patients. Clin Cancer Res 7 (8), 2468-2474.
131. Liu SS, Tsang BK, Cheung AN, et al. (2001). Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 37 (9), 1104-1110.
132. Ramp U, Krieg T, Caliskan E, et al. (2004). XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 35 (8), 1022-1028.
133. Altieri DC (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (1), 46-54.
134. Imoto I, Tsuda H, Hirasawa A, et al. (2002). Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 62 (17), 4860-4866.
135. Atikcan S, Unsal E, Demirag F, Koksal D, and Yilmaz A (2006). Correlation between survivin expression and prognosis in non-small cell lung cancer. Respir Med. doi: 10.1016/J.rmed.2006.02.031.
136. Schultz IJ, Witjes JA, Swinkels DW, and de Kok JB (2006). Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin Chim Acta 368 (1-2), 20-32.
137. Bloom J and Pagano M (2003). Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 13 (1), 41-47.
138. Ougolkov A, Zhang B, Yamashita K, et al. (2004). Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer. J Natl Cancer Inst 96 (15), 1161-1170.
139. Koch A, Waha A, Hartmann W, et al. (2005). Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 11 (12), 4295-4304.
140. Spiegelman VS, Tang W, Chan AM, et al. (2002). Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J Biol Chem 277 (39), 36624-36630.
141. Saitoh T and Katoh M (2001). Expression profiles of betaTRCP1 and betaTRCP2, and mutation analysis of betaTRCP2 in gastric cancer. Int J Oncol 18 (5), 959-964.
142. Fuchs SY, Spiegelman VS, and Kumar KG (2004). The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23 (11), 2028-2036.
143. Nag A, Bagchi S, and Raychaudhuri P (2004). Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res 64 (22), 8152-8155.
144. Bondar T, Kalinina A, Khair L, et al. (2006). Cul4A and DDB1 associate with Skp2 to target p27Kip1 for proteolysis involving the COP9 signalosome. Mol Cell Biol 26 (7), 2531-2539.
145. Chen LC, Manjeshwar S, Lu Y, et al. (1998). The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 58 (16), 3677-3683.
146. Yasui K, Arii S, Zhao C, et al. (2002). TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 35 (6), 1476-1484.
147. Sasaki H, Yukiue H, Kobayashi Y, et al. (2001). Expression of the sensitive to apoptosis gene, SAG, as a prognostic marker in nonsmall cell lung cancer. Int J Cancer 95 (6), 375-377.
148. Ciechanover A and Iwai K (2004). The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 56 (4), 193-201.
149. Richardson PG, Mitsiades C, Hideshima T, and Anderson KC (2006). Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57, 33-47.
150. Chauhan D, Catley L, Li G, et al. (2005). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8 (5), 407-419.